Deferred Revenue
Regeneron Pharmaceuticals Deferred Revenue increased by 15.0% to $636.20M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 2.7%, from $619.30M to $636.20M. Over 5 years (FY 2020 to FY 2025), Deferred Revenue shows relatively stable performance with a -0.9% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase is generally positive, signaling strong future demand and cash collection, while a decrease indicates the fulfillment of obligations.
Detailed definition
This represents payments received from customers for goods or services that have not yet been delivered or performed. It...
Peer comparison
Common in subscription and long-term contract businesses; highly indicative of future revenue visibility.
deferred_revenue_currentHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $520.00M | $507.80M | $442.00M | $491.30M | $566.30M | $547.20M | $477.90M | $426.30M | $381.10M | $417.30M | $458.90M | $516.70M | $586.00M | $627.20M | $627.70M | $619.30M | $481.90M | $545.60M | $553.00M | $636.20M |
| QoQ Change | — | -2.3% | -13.0% | +11.2% | +15.3% | -3.4% | -12.7% | -10.8% | -10.6% | +9.5% | +10.0% | +12.6% | +13.4% | +7.0% | +0.1% | -1.3% | -22.2% | +13.2% | +1.4% | +15.0% |
| YoY Change | — | — | — | — | +8.9% | +7.8% | +8.1% | -13.2% | -32.7% | -23.7% | -4.0% | +21.2% | +53.8% | +50.3% | +36.8% | +19.9% | -17.8% | -13.0% | -11.9% | +2.7% |
Deferred Revenue at Other Companies
Frequently Asked Questions
- What is Regeneron Pharmaceuticals's deferred revenue?
- Regeneron Pharmaceuticals (REGN) reported deferred revenue of $636.20M in Q1 2026.
- How has Regeneron Pharmaceuticals's deferred revenue changed year-over-year?
- Regeneron Pharmaceuticals's deferred revenue increased by 2.7% year-over-year, from $619.30M to $636.20M.
- What is the long-term trend for Regeneron Pharmaceuticals's deferred revenue?
- Over 5 years (2020 to 2025), Regeneron Pharmaceuticals's deferred revenue has grown at a -0.9% compound annual growth rate (CAGR), from $577.70M to $553.00M.
- What does deferred revenue mean?
- Cash received from customers for work that has not yet been completed.